rethinkPeptides Search
Menu
Study breakdown

Meningitis Bacteria Use a Negatively Charged Protein Shield to Defend Against Antimicrobial Peptides

evidence
The takeaway

Neisseria meningitidis uses negatively charged regions of its surface protein LbpB to neutralize the antimicrobial peptide lactoferricin, providing greater protection than its capsule.

LbpB > capsule protection

The bacterial surface protein LbpB provided greater defense against the antimicrobial peptide lactoferricin than the polysaccharide capsule in Neisseria meningitidis

What the researchers found

The negatively charged regions of lactoferrin binding protein B (LbpB) in Neisseria meningitidis are essential for protecting the bacteria against lactoferricin, a cationic antimicrobial peptide. Removing these negatively charged regions eliminated LbpB's protective effect while maintaining the protein's structural stability. LbpB provided greater protection against lactoferricin than the bacterial polysaccharide capsule, suggesting it is a major defense mechanism against host antimicrobial peptides. The selective release of LbpB from the cell surface by the autotransporter NalP may serve primarily for immune evasion rather than iron acquisition.

Why it matters

Understanding how pathogenic bacteria defend themselves against the body's natural antimicrobial peptides is crucial for developing new anti-infective strategies. This study reveals that LbpB acts as a shield specifically neutralizing cationic antimicrobial peptides like lactoferricin, which could be exploited to make bacteria more vulnerable to these natural immune defenses.

The numbers in context

LbpB protection > capsule protection · negatively charged regions conserved across all species except Moraxella bovis · C-terminal lobe location · NalP-mediated release reduces in vitro protection

How the study worked

Laboratory study using Neisseria meningitidis. Researchers engineered LbpB variants with negatively charged regions removed and tested bacterial survival against lactoferricin in killing assays. The role of NalP-mediated LbpB release and polysaccharide capsule protection were also assessed. Protein stability was verified to ensure mutations didn't simply destroy the protein.

Who was studied

Neisseria meningitidis bacterial strains with wild-type and modified LbpB (in vitro laboratory study)

What this study cannot tell us

In vitro killing assays may not fully replicate in vivo conditions where NalP release and capsule dynamics differ. The study focused on lactoferricin specifically and did not test other antimicrobial peptides. The proposed in vivo functions are inferred but not directly demonstrated in animal infection models.

How to read the evidence

Well-designed in vitro laboratory study with appropriate controls (engineered mutants, stability verification). Provides mechanistic insight but lacks in vivo validation. The conservation of negatively charged regions across species supports biological relevance.

When this study was published

Published in 2014, this study provides foundational knowledge about bacterial defenses against antimicrobial peptides. The findings remain relevant as antimicrobial peptide drug development continues to advance.

The bigger picture

Antimicrobial peptides are considered promising alternatives to traditional antibiotics, but bacteria have evolved resistance mechanisms. Understanding these defenses — like LbpB acting as an electrostatic shield — is essential for designing antimicrobial peptides that can evade bacterial countermeasures and for identifying drug targets that could disarm these bacterial defenses.

Questions still open

  • Could targeting or disrupting LbpB make N. meningitidis more vulnerable to the body's natural antimicrobial peptides?
  • Do other Gram-negative pathogens use similar negatively charged surface proteins to resist antimicrobial peptides?
  • Can antimicrobial peptides be engineered to overcome LbpB-mediated protection?

Common questions

What are antimicrobial peptides and how do they kill bacteria?
Antimicrobial peptides are small, positively charged proteins produced by the immune system. They kill bacteria by binding to their negatively charged cell membranes and creating pores or disrupting the membrane, causing the bacteria to die. Lactoferricin is one such peptide released from the milk protein lactoferrin.
How does this help in fighting antibiotic resistance?
Antimicrobial peptides are being developed as alternatives to traditional antibiotics. Understanding how bacteria like N. meningitidis resist these peptides — through electrostatic shielding by LbpB — helps researchers design peptides that can overcome these defenses or develop drugs that disable bacterial protection mechanisms.

Read the original research

The negatively charged regions of lactoferrin binding protein B, an adaptation against anti-microbial peptides.

PloS one, 9(1), e86243

Citation

Morgenthau, Ari; Beddek, Amanda; Schryvers, Anthony B. (2014). The negatively charged regions of lactoferrin binding protein B, an adaptation against anti-microbial peptides.. PloS one, 9(1), e86243. https://doi.org/10.1371/journal.pone.0086243